Dipyrone

PMID: 30000586

Abstract:

Dipyrone is not approved for marketing in the United States by the U.S. Food and Drug Administration or in Canada and many European countries because of its adverse reactions, including agranulocytosis. However, it is widely used in other countries during labor and breastfeeding.[1][2][3][4] After ingestion by the mother, dipyrone and its metabolites appear in breastmilk in rather large amounts. It is found in the blood and urine of breastfed infants and can cause pharmacological effects in the breastfed infant. One case of cyanotic episodes in a breastfed infant was attributed to dipyrone in breastmilk. The drug and metabolites are eliminated from the breastmilk by 48 hours after a dose and one manufacturer recommends no breastfeeding for 48 hours after a dose.[5] Safer alternatives are available for analgesia during breastfeeding.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
ALP81693223	3′-N-Acetylneuraminyl-N-acetyllactosamine sodium salt		81693-22-3 (free acid)	Price
AP124052046	Sodium pyruvate-3-13C		124052-04-6	Price
AP296250549	BMS-341400 methanesulfonate		296250-54-9	Price
AP321863212	2-Oleoyl-1-palmitoyl-sn-glycero-3-phospho-L-serine sodium salt		321863-21-2	Price
AP73548693	1,2-Dilauroyl-sn-glycero-3-phosphorylglycerol sodium salt		73548-69-3	Price